«Where should digital biology stop?»
Deep genomics, AI drug discovery, CRISPR, cancer vaccines, longevity. The human as a platform for updates - and the price of error.
Sequencing costs fell faster than Moore’s law.
The first CRISPR therapies are approved and used in the clinic.
Longevity: medicine or marketing. Data versus promises.
A strong clinical school - and open questions of regulation and access.
Names are published only after written confirmation of participation. The line-up may change; ticket holders hear about changes first.
Cohort openings, party invitations, the odd confession. Once a fortnight at most, and never boring - we'd be too embarrassed.